BamSEC and AlphaSense Join Forces
Learn More

Alexion Pharmaceuticals, Inc.

Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 113 pages Agreement and Plan of Merger Dated as of December 12, 2020 Among Astrazeneca PLC, Delta Omega Sub Holdings Inc., Delta Omega Sub Holdings Inc. 1, Delta Omega Sub Holdings LLC 2 and Alexion Pharmaceuticals, Inc
12/34/56
EX-2.1
from 425 113 pages Agreement and Plan of Merger Dated as of December 12, 2020 Among Astrazeneca PLC, Delta Omega Sub Holdings Inc., Delta Omega Sub Holdings Inc. 1, Delta Omega Sub Holdings LLC 2 and Alexion Pharmaceuticals, Inc
12/34/56
EX-2.1
from SC TO-C 103 pages Agreement and Plan of Merger by and Among Portola Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Odyssey Merger Sub Inc. May 5, 2020
12/34/56
EX-2.1
from 8-K 103 pages Agreement and Plan of Merger by and Among Portola Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Odyssey Merger Sub Inc. May 5, 2020
12/34/56
EX-2.1
from 8-K 122 pages Agreement and Plan of Merger Dated as of October 15, 2019 Among Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Beagle Merger Sub, Inc
12/34/56
EX-2.1
from 8-K 87 pages Agreement and Plan of Reorganization by and Among Alexion Pharmaceuticals, Inc., Pulsar Merger Sub Inc., Galaxy Merger Sub LLC, and Synageva Biopharma Corp. Dated as of May 5, 2015
12/34/56
EX-2.1
from 425 87 pages Agreement and Plan of Reorganization by and Among Alexion Pharmaceuticals, Inc., Pulsar Merger Sub Inc., Galaxy Merger Sub LLC, and Synageva Biopharma Corp. Dated as of May 5, 2015
12/34/56
EX-2.1
from 8-K 8 pages First Amendment to Agreement and Plan of Merger
12/34/56
EX-2.1
from 8-K 131 pages Omitted Information Is the Subject of a Request for Confidential Treatment Pursuant to Rule 24b-2 Under the Securities Exchange Act of 1934 and Has Been Filed Separately With the Securities and Exchange Commission. Agreement and Plan of Merger by and Among Alexion Pharmaceuticals, Inc., Emrd Corporation, M. Luc Mainville, Jonathan Silverstein, Robert Heft and David Bonita as the Stockholder Representatives and Enobia Pharma Corp. Dated as of December 28, 2011
12/34/56
EX-2.1
from 8-K 165 pages Omitted Information Is the Subject of a Request for Confidential Treatment Pursuant to Rule 24b-2 Under the Securities Exchange Act of 1934 and Has Been Filed Separately With the Securities and Exchange Commission
12/34/56
EX-2.1
from SC 13G/A 1 page Statement of Control Person
12/34/56
EX-2.1
from SC 13G/A 1 page Statement of Control Person
12/34/56
EX-2.1
from SC 13G/A 1 page Statement of Control Person
12/34/56
EX-2.1
from 8-K >50 pages Agreement and Plan of Merger
12/34/56
EX-2
from SC 13D/A 1 page Power of Attorney in Favor of Dr. Andreas Hove
12/34/56
EX-2
from SC 13D 1 page Power of Attorney in Favor of Dr. Andreas Hove
12/34/56
EX-2
from 8-K 1 page Form of Stockholder's Letter
12/34/56